Total Valuation
Kyongbo Pharmaceutical Co., Ltd. has a market cap or net worth of ₩121.69B. The enterprise value is ₩304.25K.
Market Cap₩121.69B
Enterprise Value₩304.25K
Share Statistics
Kyongbo Pharmaceutical Co., Ltd. has 23,906,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,906,860
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kyongbo Pharmaceutical Co., Ltd.’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 0.52%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)0.52%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee522.98M
Profits Per Employee213.95K
Employee Count505
Asset Turnover0.83
Inventory Turnover2.05
Valuation Ratios
The current PE Ratio of Kyongbo Pharmaceutical Co., Ltd. is 478.8. Kyongbo Pharmaceutical Co., Ltd.’s PEG ratio is -7.87.
PE Ratio478.8
PS Ratio0.52
PB Ratio0.95
Price to Fair Value0.95
Price to FCF-4.04
Price to Operating Cash Flow10.83
PEG Ratio-7.87
Income Statement
In the last 12 months, Kyongbo Pharmaceutical Co., Ltd. had revenue of 264.10B and earned 182.29M in profits. Earnings per share was 7.63.
Revenue264.10B
Gross Profit97.82B
Operating Income3.52B
Pretax Income449.49M
Net Income182.29M
EBITDA16.72B
Earnings Per Share (EPS)7.63
Cash Flow
In the last 12 months, operating cash flow was 11.23B and capital expenditures -50.96B, giving a free cash flow of -39.73B billion.
Operating Cash Flow11.23B
Free Cash Flow-39.73B
Free Cash Flow per Share-1.66K
Dividends & Yields
Kyongbo Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change0.47%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)40.58K
Important Dates
Kyongbo Pharmaceutical Co., Ltd. upcoming earnings date is Aug 19, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 19, 2026
Ex-Dividend Date―
Financial Position
Kyongbo Pharmaceutical Co., Ltd. as a current ratio of 1.08, with Debt / Equity ratio of 99.12%
Current Ratio1.08
Quick Ratio0.53
Debt to Market Cap0.91
Net Debt to EBITDA7.14
Interest Coverage Ratio0.82
Taxes
In the past 12 months, Kyongbo Pharmaceutical Co., Ltd. has paid 267.20M in taxes.
Income Tax267.20M
Effective Tax Rate0.59
Enterprise Valuation
Kyongbo Pharmaceutical Co., Ltd. EV to EBITDA ratio is 15.38, with an EV/FCF ratio of -7.55.
EV to Sales0.97
EV to EBITDA15.38
EV to Free Cash Flow-7.55
EV to Operating Cash Flow34.50
Balance Sheet
Kyongbo Pharmaceutical Co., Ltd. has ₩9.95B in cash and marketable securities with ₩143.03B in debt, giving a net cash position of -₩133.08B billion.
Cash & Marketable Securities₩9.95B
Total Debt₩143.03B
Net Cash-₩133.08B
Net Cash Per Share-₩5.57K
Tangible Book Value Per Share₩5.93K
Margins
Gross margin is 38.47%, with operating margin of 1.33%, and net profit margin of 0.07%.
Gross Margin38.47%
Operating Margin1.33%
Pretax Margin0.17%
Net Profit Margin0.07%
EBITDA Margin6.33%
EBIT Margin1.33%
Analyst Forecast
The average price target for Kyongbo Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast14.83%
EPS Growth Forecast1148.18%